Alimera Sciences News Releases https://investor.alimerasciences.com/ Alimera Sciences News Releases en Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 https://investor.alimerasciences.com/news-releases/news-release-details/alimera-sciences-present-20th-annual-b-riley-fbr-institutional ATLANTA , May 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that President and CEO, Rick Eiswirth will present a corporate overview and meet with investors at the Tue, 14 May 2019 08:05:00 -0400 Alimera Sciences News Releases 12626 Alimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview https://investor.alimerasciences.com/news-releases/news-release-details/alimera-sciences-announces-first-quarter-2019-financial-results First Quarter and Recent Company Highlights: Global revenue up 34% versus Q1 2018 Regulatory approval obtained for ILUVIEN ® in 17 EU countries for the treatment of Non-Infectious Posterior Uveitis Samer Kaba , M.D. appointed to new position of Chief Medical Officer National pricing and Mon, 29 Apr 2019 16:15:00 -0400 Alimera Sciences News Releases 12581 Alimera Sciences to Report First Quarter Financial Results on Monday, April 29, 2019 and Provide Corporate Update https://investor.alimerasciences.com/news-releases/news-release-details/alimera-sciences-report-first-quarter-financial-results-monday Conference Call to be held Tuesday April 30, 2019 at 9:00am Eastern Time ATLANTA, (April 23, 2019) – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that it will report first quarter 2019 Tue, 23 Apr 2019 16:30:00 -0400 Alimera Sciences News Releases 12571 Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIEN® to be Presented at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting https://investor.alimerasciences.com/news-releases/news-release-details/alimera-sciences-announces-multiple-posters-and-podium ATLANTA, (April 23, 2019) – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that clinical data for ILUVIEN ® will be featured in 15 posters and one podium presentation at the Association for Tue, 23 Apr 2019 08:30:00 -0400 Alimera Sciences News Releases 12566 Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer https://investor.alimerasciences.com/news-releases/news-release-details/alimera-sciences-announces-expansion-leadership-team-appointment ATLANTA, April 4, 2019 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced an expansion of its leadership team with the appointment of Samer Kaba, MD as Chief Medical Officer, effective April Thu, 04 Apr 2019 08:00:00 -0400 Alimera Sciences News Releases 12551 Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN® in Europe https://investor.alimerasciences.com/news-releases/news-release-details/alimera-sciences-announces-approval-received-mutual-recognition Indication for treatment of non-infectious posterior uveitis further supports the uniqueness of ILUVIEN to consistently and continuously deliver treatment to reduce the recurrence of inflammation Regulatory process to now enter the national phase in which each member state finalizes the label to Mon, 25 Mar 2019 09:30:00 -0400 Alimera Sciences News Releases 12541 Alimera Sciences Announces Approval For ILUVIEN® in Kuwait https://investor.alimerasciences.com/news-releases/news-release-details/alimera-sciences-announces-approval-iluvienr-kuwait Kuwait added to the growing number of countries with approval for ILUVIEN in the Middle East ATLANTA, March 21, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera) , a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN has Thu, 21 Mar 2019 08:00:00 -0400 Alimera Sciences News Releases 12536 Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in France https://investor.alimerasciences.com/news-releases/news-release-details/alimera-sciences-announces-reimbursement-iluvienr-france France is a Significant Market for Intravitreal Steroid Use ATLANTA, GA / ACCESSWIRE / March 6, 2019 /  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that its subsidiary, Alimera Wed, 06 Mar 2019 08:00:00 -0500 Alimera Sciences News Releases 12531 Alimera Sciences Reports Record Fourth Quarter and 2018 Results https://investor.alimerasciences.com/news-releases/news-release-details/alimera-sciences-reports-record-fourth-quarter-and-2018-results Fourth Quarter 2018 Highlights Fourth quarter 2018 consolidated net revenue up 66% International segment revenue increased 138% over the prior year period Net Loss of $1.2 million vs. Net Loss of $7.2 million during 4Q17 Positive Adjusted EBITDA of $2.4 million vs. Mon, 18 Feb 2019 16:15:00 -0500 Alimera Sciences News Releases 12501 Alimera Sciences Announces Approval For ILUVIEN® in Lebanon https://investor.alimerasciences.com/news-releases/news-release-details/alimera-sciences-announces-approval-iluvienr-lebanon Lebanon will be the second Middle Eastern country to approve ILUVIEN   ATLANTA, February 5, 2018 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that product registration has been Tue, 05 Feb 2019 07:30:00 -0500 Alimera Sciences News Releases 12436